

**CORDLIFE GROUP LIMITED**  
(Company Registration No.: 200102883E)  
(Incorporated in the Republic of Singapore)

---

**PROFIT WARNING ON THE UNAUDITED FINANCIAL RESULTS FOR THE  
SIX MONTHS ENDED 30 JUNE 2024**

---

The Board of Directors of Cordlife Group Limited (the "**Company**" and together with its subsidiaries, the "**Group**") wishes to announce that, based on a preliminary assessment of the Group's draft unaudited financial results for the six months ended 30 June 2024 ("**1H2024**" and such results, the "**Unaudited 1H2024 Results**"), the Group expects to report a material decline in profit for 1H2024 as compared to the six months ended 30 June 2023 ("**1H2023**").

As stated in the Company's announcements on 30 November 2023, 13 December 2023, 15 December 2023 and 23 January 2024, the Company had, among others, accepted the notice from the Ministry of Health ("**MOH**") to stop for a period of up to six months, the collection, testing, processing and/or storage of any new cord blood and human tissues, or the provision of any new types of tests to patients in Singapore, and is working with the MOH to rectify any potential areas of non-compliance with the Healthcare Services (General) Regulations and the Healthcare Services (Cord Blood Banking Services) Regulations that the MOH has identified in relation to the Company's operations in Singapore.

As announced by the Company on 8 April 2024, the Company has also offered to refund annual fees received from the start of the temperature excursions and waive subsequent fees for active clients who have stored cord blood units in the cryogenic storage tank and dry shipper that were deemed by the expert panel of the MOH to be at high risk of being adversely affected by the temperature excursions (the "**Refund/Waiver for High-Risk Tanks**"), and the Company had estimated that the refund and waiver of annual fees for all affected active clients would result in a decrease in revenue and profit before tax of approximately S\$9.2 million.

As announced by the Company on 28 May 2024, the MOH had on 27 May 2024 issued a further notice to the Company to stop the collection, testing, processing and/or storage of any new cord blood for up to an additional three months with effect on and from 15 June 2024, or unless sooner approved by the Director-General of Health (the "**Second Notice**"), and the Second Notice was issued after the MOH had conducted further inspections on the Company in April and May 2024 and informed the Company of its finding that, among others, the Company has yet to complete the validation of the AXP II System for cord blood processing, the development of its relevant operating procedures and practices for the AXP II System, and the training and competency assessment of its staff in using the system. On 18 June 2024, the Company announced that it had received a letter from the MOH, directing it to give effect to the contents of the Second Notice with effect on and from 15 June 2024 (the "**18 June Announcement**").

The Company had, on 11 June 2024, in its quarterly business update for the three months ended 31 March 2024 ("**1Q2024**") and accompanying press release, announced that the financial impact of the Refund/Waiver for High-Risk Tanks resulted in a revenue reversal of approximately S\$9.7 million (which also includes the recognition of S\$0.5 million of contract liabilities relating to the future storage obligations for all active clients in the High-Risk Tanks) in 1Q2024 and that the further suspension pursuant to the Second Notice is expected to continue to have a negative financial impact on the Group. In its 18 June

Announcement, the Company had likewise stated that the continued suspension of the Group's operations in Singapore in relation to its cord blood banking services, along with the fixed costs being incurred during such suspension, is expected to continue to have a negative financial impact on the Group.

In connection with the above and based on a preliminary assessment of the information currently available to the Board (including the draft Unaudited 1H2024 Results), the Company anticipates that it will incur a net loss for 1H2024 as compared to a net profit for 1H2023. Additionally, while the Company will recognise the financial impact of the Refund/Waiver for High-Risk Tanks in 1H2024, the investigations by the MOH are ongoing and there is no certainty on the outcome of the MOH's ongoing investigations.

This profit warning is based on a preliminary review of the Group's draft Unaudited 1H2024 Results. Further details will be disclosed when the Group announces its Unaudited 1H2024 Results, which will be released on or before 14 August 2024.

In the meantime, shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company. They should consult their stockbrokers, bank managers, solicitors, or other professional advisers if they have any doubt about the actions they should take.

By order of the Board  
**CORDLIFE GROUP LIMITED**

Sharon Lim Siew Choo  
Goh Xun Er  
Company Secretaries

12 August 2024